Date: April 2, 2026 Persona: GauchoRico Market Cap: ~2.76B(30.39 x 90.9M shares) EV/TTM Revenue: ~5.6x ($2.75B EV / 490.7M) * *FY25RevenueGrowth : * * +110.3 * *StockPrice : ** 30.39 | 52-week range: 12.91−42.13 FSGS PDUFA: April 13, 2026 (11 days away)
Holy smokes -- this is one of the most compelling risk/reward setups I've seen in a long time. Travere is a specialty pharma company that has gone from a chronic cash-burner to an operational inflection point, driven by FILSPARI, a first-in-class kidney drug with 98% gross margins growing at 144% YoY. The company trades at an EV/TTM Revenue of 5.6x on 110% revenue growth -- that's a PEG of 0.05. I can count on one hand the number of times I've seen a PEG that low on a company with this quality of growth.
The kicker: the FSGS PDUFA decision on April 13 could approximately double the addressable market. If approved, FILSPARI would be the first and only drug approved for FSGS -- an uncontested indication. That's the kind of competitive dominance I look for.
But let's be rigorous. The DUPLEX trial missed its primary eGFR slope endpoint at 108 weeks, even though it hit the pre-specified interim proteinuria endpoint and showed lower rates of end-stage kidney disease. The FDA classified Travere's additional response as a "Major Amendment" -- not routine. While the AdCom removal is a bullish signal, this is NOT a guaranteed approval. I want to be honest about that binary risk.
Conviction: 4/5. If I didn't have the binary FSGS event 11 days out, this would be 5/5 on fundamentals alone. The binary risk keeps it at 4.
Revenue YoY% QoQ% GM%[GAAP] OpMrg[GAAP] OpMrg[Non-GAAP] EPS[GAAP] EPS[Non-GAAP]
Q1'23 $30.9M +32.1% +5.5% 86.7% -315% -- -$1.27 --
Q2'23 $32.2M +12.6% +4.2% 95.3% -323% -- -$1.13 --
Q3'23 $37.1M +32.0% +15.2% 96.5% -250% -- +$1.97* --
Q4'23 $45.1M +53.9% +21.6% 89.8% -209% -- -$1.18 --
Q1'24 $41.4M +34.0% -8.2% 96.4% -336% -- -$1.76 --
Q2'24 $54.1M +68.0% +30.7% 96.1% -125% -- -$0.91 --
Q3'24 $62.9M +69.5% +16.3% 97.5% -89% -- -$0.70 --
Q4'24 $74.8M +65.9% +18.9% 96.5% -81% -- -$0.71 --
Q1'25 $81.7M +97.3% +9.2% 94.2% -52% -23% -$0.47 --
Q2'25 $114.4M +111.5% +40.0% 98.7% -11% +11% -$0.14 +$0.13
Q3'25 $164.9M +162.2% +44.1% 99.0% +15% +32% +$0.28 +$0.59
Q4'25 $129.7M +73.4% -21.3% 98.0% -25% -2% +$0.03 +$0.37Q3'23 EPS anomaly from $150.7M discontinued operations gain -- not recurring.
FY25 Full Year: 490.7M(+110.325.5M (-0.29/share)|Non − GAAPNI : +81.1M (+$0.91/share)
This is where the story really gets exciting. FILSPARI is the engine that drives everything:
FILSPARI QoQ% YoY% Tiopronin License Total
Q1'24 $19.8M -- -- $20.1M $1.5M $41.4M
Q2'24 $27.1M +37% -- $25.1M $1.9M $54.1M
Q3'24 $35.6M +31% -- $25.4M $1.9M $62.9M
Q4'24 $49.6M +39% -- $23.9M $1.3M $74.8M
FY24: $132.2M $233.2M
Q1'25 $55.9M +13% +182% $20.0M $5.9M $81.7M
Q2'25 $71.9M +29% +165% $23.0M $19.6M $114.4M
Q3'25 $90.9M +26% +155% $22.3M $51.7M $164.9M
Q4'25 $103.3M +14% +108% $23.3M $3.1M $129.7M
FY25: $322.0M (+144%) $88.5M $80.3M $490.7MKey observations:
Q2'25: 745 new PSFs
Q3'25: 731 new PSFs (slight dip -- I didn't love that)
Q4'25: 908 new PSFs (all-time high! +24% QoQ)This is the number that has me most excited. PSFs are a leading indicator -- it takes weeks to months for a new patient start form to convert into a filled prescription and actual revenue. 908 PSFs in Q4 is an all-time record and a strong re-acceleration after the Q3 dip. This signals robust demand momentum going into Q1 FY26.
Annual OCF Annual FCF
FY23: -$325.4M --
FY24: -$230.0M --
FY25: +$37.8M -$20.4MFY25 is the first year of positive operating cash flow in Travere's history. The company went from burning $325M/year to generating 38M.FCFisstillslightlynegative(−20.4M) due to $58.2M in capitalized intangibles/royalty investments, but the underlying product business is OCF-positive. That's the inflection I want to see.
If capex normalizes to 5-10% of revenue in FY26 (say $30-50M on $600M+ revenue), FCF should turn positive for the first time.
The balance sheet has dramatically improved. Net cash positive, dilution slowing, no need for equity raises ahead. Sufficient runway to reach GAAP profitability without dilution.
FY25 total revenue growth of 110% is exceptional. FILSPARI at 144% is the driver. Even stripping out lumpy license revenue, net product sales grew 81%. Annual growth has been accelerating: 33% (FY23) to 60% (FY24) to 110% (FY25). This is far above my 30% threshold.
The quarterly YoY deceleration from 97% (Q1) to 73% (Q4) is base-effect driven and completely expected for a post-launch S-curve. I'm not concerned about this.
Annual trajectory is strongly accelerating. This is year 2 of a commercial drug launch -- we're still in the steep part of the S-curve. PSF count re-accelerated to an all-time high of 908 in Q4, which is the best forward indicator I can ask for.
The quarterly moderation (QoQ FILSPARI: +39% in Q4'24 to +14% in Q4'25) reflects the maturing base, not demand weakness. The absolute quarterly adds in FILSPARI are still strong: +$12.4M from Q3 to Q4 FY25.
If FSGS is approved, trajectory re-accelerates from an entirely new demand vector.
98% GAAP gross margins. Let me say that again -- 98%. This is higher than virtually every SaaS company I've ever analyzed. CRM at its best was running 87-91% subscription margins. FILSPARI has essentially zero COGS -- this is specialty pharma economics at its finest.
COGS was only $10.3M on $490.7M revenue in FY25. The revenue falls almost entirely to gross profit.
This is the one area where I need to be measured.
Strengths:
Threats:
My assessment: The competitive landscape is intensifying, no question. But this is more analogous to the early immune-oncology market than a zero-sum share fight. The IgAN market was ~$878M in 2025 across major markets (DelveInsight) and growing at 30%+ CAGR. There's room for multiple drugs. FILSPARI's KDIGO endorsement + first-mover + dual mechanism create a durable moat within this expanding market.
If FSGS is approved, FILSPARI gets an entirely uncontested indication. No other drug is approved for FSGS. That's the kind of dominance I give the highest allocation to.
| Metric | Value | Assessment |
|---|---|---|
| EV/TTM Revenue | 5.6x | Mid-range for specialty pharma; cheap for 110% grower |
| P/S (TTM) | 5.7x | |
| P/E (Non-GAAP FY25) | ~30x | Fair for profitability inflection |
| PEG (P/S / Growth%) | 0.05 | Exceptionally cheap |
| Rule of 40 (FY25) | 117% | Exceptional |
Let me benchmark this against the CRM Case Study. When CRM was growing revenue at 50%+ with 87% subscription gross margins and 20%+ FCF margins, it traded at 8-12x EV/TTM Sales. TVTX is growing at 110% with 98% gross margins and approaching FCF positive, and trades at 5.6x.
Even a mid-cap biotech peer cohort growing 20-40% trades at 4-6x. TVTX is growing 3-5x faster at a comparable multiple.
The PEG of 0.05 is the lowest I've seen on a company with this quality of metrics. The market is either pricing in (a) FSGS rejection, (b) severe competitive erosion, or (c) simply hasn't caught up with the financial inflection.
FSGS PDUFA -- April 13, 2026. This is the defining event for the next 12 months:
Critical nuance the market is focused on: The DUPLEX Phase 3 trial missed its primary eGFR slope endpoint at 108 weeks. It DID hit the pre-specified interim proteinuria endpoint at 36 weeks, and showed higher remission rates and lower ESRD vs active control. But the primary endpoint miss is a real concern for FDA approval. The FDA's "Major Amendment" classification of Travere's additional response adds uncertainty.
Bullish counter: AdCom was removed -- meaning FDA feels confident enough to make the decision internally. No new safety or manufacturing data was requested. The supplemental filing emphasized proteinuria as a reasonably likely surrogate endpoint (which is the basis for accelerated approvals in kidney disease). And there is literally no other approved drug for FSGS.
Additional catalysts:
I find it helpful to compare growth companies to CRM's long trajectory. Where does TVTX sit?
| Metric | CRM (2007, ~$500M rev) | TVTX (FY25, $491M rev) |
|---|---|---|
| Revenue | ~$497M | $490.7M |
| Revenue Growth | ~55% YoY | +110% YoY |
| Gross Margin | ~87% (subscription) | 98% (GAAP blended) |
| FCF Margin | ~20% | ~-4% (FY25; OCF +7.7%) |
| EV/TTM Sales | ~10x | ~5.6x |
| Competitive Position | Dominant (#1 cloud CRM) | Strong first-mover (IgAN), potentially dominant (FSGS) |
| Share Dilution | ~3-5%/yr | ~2.1% FY25 |
At a similar revenue scale, CRM traded at 10x EV/Sales while growing half as fast. TVTX grows twice as fast with higher gross margins and trades at half the multiple. The gap is FCF -- CRM was already generating 20%+ FCF margins at this stage, while TVTX is just crossing the OCF-positive threshold.
If TVTX can demonstrate FCF positive in FY26 (which is plausible given current trajectory + FSGS), the valuation gap should compress substantially.
FY25 Actual FY26 Base Case FY26 Bull Case FY26 Bear Case
(FSGS approved, (FSGS approved, (FSGS rejected)
moderate ramp) strong ramp)
FILSPARI IgAN $322M $400-420M $420-450M $380-400M
FILSPARI FSGS -- $30-50M $50-80M $0
Tiopronin $88.5M $85-90M $85-90M $85-90M
License/Royalties $80.3M $30-40M $35-45M $15-25M
Total Revenue $490.7M $545-600M $590-665M $480-515M
Non-GAAP Op Margin +8.7% +18-22% +22-28% +10-15%
Non-GAAP EPS $0.91 $1.40-1.80 $1.80-2.40 $0.80-1.10Notes on FY26 guidance: Management guided "meaningful growth" for FILSPARI, GTN headwind to mid-20% (from ~20% in FY25), and moderate opex growth. No dollar targets. I interpret "meaningful" as 25%+ net product sales growth (IgAN alone = $400M+).
GTN headwind quantified: 500bps of GTN expansion on 450M + FILSPARIgrosssales= 22-25M net revenue drag. Real but manageable against $100M+ of absolute FILSPARI growth.
| Scenario | FY26 Revenue | P/S Multiple | Market Cap | Share Price | vs Current |
|---|---|---|---|---|---|
| Bull (FSGS + strong execution) | $650M | 6.5x | $4.2B | ~$46 | +52% |
| Base (FSGS + moderate GTN) | $575M | 5.5x | $3.2B | ~$35 | +15% |
| Bear (FSGS rejected) | $490M | 4.0x | $2.0B | ~$22 | -27% |
The asymmetry is favorable: +52% bull vs -27% bear. And the bear case is conservative -- even without FSGS, the IgAN franchise alone generates $400M+ product revenue growing mid-20%+. At 4x P/S on a mid-20% grower with 98% gross margins, the floor feels solid.
This is a classic "fat pitch" setup in many ways -- dominant product, inflecting financials, binary catalyst, attractive valuation. The kind of opportunity where I'd normally be reaching for LEAPS.
However, caution is warranted. The FSGS decision is 11 days away. Near-term options would be pure binary bets -- that's speculation, not investing. If I were to use LEAPS, I'd want:
I would NOT buy LEAPS pre-PDUFA. The binary risk is too high for leveraged exposure.
Prior Beliefs: No prior coverage of TVTX. First analysis.
Updated Beliefs:
TVTX is a specialty pharma company at a rare dual inflection -- revenue inflection (110% growth) and profitability inflection (first year of positive OCF, approaching GAAP breakeven) -- driven by FILSPARI, a first-in-class drug with 98% gross margins and demonstrable clinical superiority in IgAN. The stock trades at 5.6x EV/TTM Sales despite growing faster than nearly every company in my portfolio. The FSGS PDUFA on April 13 represents an asymmetric catalyst -- approval creates a first-and-only drug in an uncontested indication accessible by the existing sales force. Even without FSGS, the IgAN franchise alone supports current valuation.
What would change the thesis:
Action: Starter position (3-5% allocation) with plan to add on FSGS approval. This isn't my typical software company, so I'm sizing conservatively until I see the binary event resolved. If FSGS is approved and the stock pulls back after the initial pop, I'd consider LEAPS (Jan 2028 $35-40 calls) on the ramp.
If FSGS is rejected and the stock drops to $20-22, I'd look to add -- the IgAN-only thesis at 4x P/S on 25%+ growth with 98% margins is still compelling.
Thesis Status: New position -- Intact.
We will see what happens with the April 13 PDUFA decision...
briefs/TVTX_stock-analysis_2026-04-01/~/.agents/skills/atlas/analyses/TVTX/TVTX_stock-analysis_2026-04.mdGR